Evidence map›Paper›PMID 38216895›Full record

ArticleBMC musculoskeletal disorders2024

Co-development and testing of an extended community pharmacy model of service delivery for managing osteoarthritis: protocol for a sequential, multi-methods study (PharmOA).

Opeyemi O Babatunde, Elizabeth Cottrell, Simon White, Adrian Chudyk, Emma L Healey, John Edwards, Elaine Nicholls, Nicola O'Brien, Adam Todd, Christine Walker and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC musculoskeletal disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Opeyemi O BabatundeKeele University, Primary Care Centre Versus Arthritis, School of Medicine, Keele, Staffordshire, ST5 5BG, UK. o.babatunde@keele.ac.uk.
Elizabeth CottrellWolstanton Medical Centre Newcastle-Under-Lyme, Newcastle-under-Lyme, ST5 8BN, UK.
Simon WhiteKeele University, School of Pharmacy and Bioengineering, Keele, Staffordshire, UK.
Adrian ChudykKeele University, Primary Care Centre Versus Arthritis, School of Medicine, Keele, Staffordshire, ST5 5BG, UK.
Emma L HealeyKeele University, Primary Care Centre Versus Arthritis, School of Medicine, Keele, Staffordshire, ST5 5BG, UK.
John EdwardsWolstanton Medical Centre Newcastle-Under-Lyme, Newcastle-under-Lyme, ST5 8BN, UK.
Elaine NichollsKeele University, Primary Care Centre Versus Arthritis, School of Medicine, Keele, Staffordshire, ST5 5BG, UK.
Nicola O'BrienDepartment of Psychology, Northumbria University, Newcastle-Upon-Tyne, Tyne and Wear, UK.
Adam ToddNewcastle University, School of Pharmacy, Newcastle-Upon-Tyne, Tyne and Wear, UK.
Christine WalkerImpact Accelerator Unit, Keele University, Keele, Staffordshire, ST5 5BG, UK.
Colin StanfordNHS Shropshire Clinical Commissioning Group, Shrewsbury, Shropshire, UK.
Tania CorkNorth Staffs and Stoke Local Pharmaceutical Committee, Stoke-On-Trent, Staffordshire, UK.
Angela LongDepartment of Psychology, Northumbria University, Newcastle-Upon-Tyne, Tyne and Wear, UK.
Joanna SimkinsKeele University, Primary Care Centre Versus Arthritis, School of Medicine, Keele, Staffordshire, ST5 5BG, UK.
Christian D MallenKeele University, Primary Care Centre Versus Arthritis, School of Medicine, Keele, Staffordshire, ST5 5BG, UK.
Krysia DziedzicKeele University, Primary Care Centre Versus Arthritis, School of Medicine, Keele, Staffordshire, ST5 5BG, UK.
Melanie A HoldenKeele University, Primary Care Centre Versus Arthritis, School of Medicine, Keele, Staffordshire, ST5 5BG, UK.
Keele University · GBVersus Arthritis · GBNorthumbria University · GBNewcastle University · GB

Funding

Versus Arthritis 21019
6 · The paper itself

Abstract

backgroundOsteoarthritis is a common, painful and disabling long-term condition. Delivery of high-quality guideline-informed osteoarthritis care that successfully promotes and maintains supported self-management is imperative. However, osteoarthritis care remains inconsistent, including under use of core non-pharmacological approaches of education, exercise and weight loss. Community pharmacies are an accessible healthcare provider. United Kingdom government initiatives are promoting their involvement in a range of long-term conditions, including musculoskeletal conditions. It is not known what an enhanced community pharmacy role for osteoarthritis care should include, what support is needed to deliver such a role, and whether it would be feasible and acceptable to community pharmacy teams. In this (PharmOA) study, we aim to address these gaps, and co-design and test an evidence-based extended community pharmacy model of service delivery for managing osteoarthritis.

methodsInformed by the Theoretical Domains Framework, Normalisation Process Theory, and the Medical Research Council (MRC) framework for developing complex interventions, we will undertake a multi-methods study involving five phases: 1. Systematic review to summarise currently available evidence on community pharmacy roles in supporting adults with osteoarthritis and other chronic (non-cancer) pain. 2. Cross-sectional surveys and one-to-one qualitative interviews with patients, healthcare professionals and pharmacy staff to explore experiences of current, and potential extended community pharmacy roles, in delivering osteoarthritis care. 3. Stakeholder co-design to: a) agree on the extended role of community pharmacies in osteoarthritis care; b) develop a model of osteoarthritis care within which the extended roles could be delivered (PharmOA model of service delivery); and c) refine existing tools to support community pharmacies to deliver extended osteoarthritis care roles (PharmOA tools). 4. Feasibility study to explore the acceptability and feasibility of the PharmOA model of service delivery and PharmOA tools to community pharmacy teams. 5. Final stakeholder workshop to: a) finalise the PharmOA model of service delivery and PharmOA tools, and b) if applicable, prioritise recommendations for its wider future implementation. DISCUSSION: This novel study paves the way to improving access to and availability of high-quality guideline-informed, consistent care for people with osteoarthritis from within community pharmacies.

Indexed as

Community Pharmacy ServicesOsteoarthritisPharmaciesAdultCross-Sectional StudiesHumansPharmacistsSystematic Reviews as TopicCommunity pharmacyOsteoarthritisPrimary careSelf-management

Identifiers

PMID38216895
PMCPMC10785546
OpenAlexW4390830580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.